Abstract
At the last meeting in this series, it became clear that the pharmacological activity of the hydroxylated metabolites ought to be considered in future clinical studies on antidepressants (Potter, 1981). Some of the genetic aspects of the metabolism of these antidepressants have been reviewed by Bertilsson et al. (1981).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alexanderson, B. and Borgå, O. (1972). Interindividual differences in plasma protein binding of nortriptyline in man — a twin study. Eur. J. Clin. Pharmacol., 4, 196–200
Alvan, C., Borgå, O., Lind, M., Palmer, L. and Siwers, B. (1977). First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma. Eur. J. Clin. Pharmacol., 11, 219–24
Balant-Gorgia, A.E., Schulz, P., Dayer, P., Balant, L., Kubli, A., Gertsch, C. and Garrone, G. (1982). Role of oxidation polymorphism on blood and urine concentration of amitriptyline and its metabolites. Arch. Psychiat. Nervenkr., 232, 215–22
Baumann, P., Tinguely, D., Koeb, L., Schöpf, J. and Le, P.K. (1982a). On the relationship between free plasma and saliva amitriptyline and nortriptyline. Int. Pharmacopsychiat., 17, 136–46
Baumann, P., Tinguely, D. and Schöpf, J. (1982b). Increase of α1-acid-glycoprotein after treatment with amitriptyline. Br. J. Clin. Pharmacol., 14, 102–3
Bertilsson, L., Alvan, G., von Bahr, C., Lind, M., Mellström, B., Säwe, J., Schulz, H.-U. and Sjöqvist, F. (1981). Active metabolites of antidepressants: novel aspects of hydroxylation and demethylation in man. In Clinical Pharmacology in Psychiatry; Neuroleptic and Antidepressant Research (ed. E. Usdin, S.G. Dahl, L.F. Gram and O. Lingjaerde), Macmillan, London, pp. 161–9
Bertilsson, L., Eichelbaum, M., Mellström, B., Säwe, J., Schulz, H.-U. and Sjöqvist, F. (1980). Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci., 27, 1673–7
Bertilsson, L., Mellström, B. and Sjöqvist, F. (1979). Pronounced inhibition of noradrenaline uptake by 10-hydroxy-metabolites of nortriptyline. Life Sci., 25, 1285–91
Borgå, O., Azarnoff, D.L., Forshell, G.P. and Sjöqvist, F. (1969). Plasma protein binding of tricyclic anti-depressants in man. Biochem. Pharmacol., 18, 2135–43
Brinkschulte, M. and Breyer-Pfaff, U. (1980). The contribution of α1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn-Schmiedeberg’sArch. Pharmacol., 314, 61–6
Burch, J.E., Roberts, S.G., and Raddats, M.A. (1981). Binding of amitriptyline and nortriptyline in plasma determined from their equilibrium distributions between red cells and plasma, and between red cells and buffer solution. Psychopharmacology, 75, 262–72
Carroll, B.J., Mukhopadhyay, S. and Feinberg, M. (1981). Radioimmunoassay of tricyclic antidepressants. In Clinical Pharmacology in Psychiatry; Neuroleptic and Antidepressant Research (ed. E. Usdin, S.G. Dahl, L.F. Gram and O. Lingjaerde), Macmillan, London, pp. 19–25.
Danhof, M. and Breimer, D.D. (1978). Therapeutic drug monitoring in saliva. Clin. Pharmacokin., 3, 39–57
De Leve, L.D. and Piafsky, K.M. (1981). Clinical significance of plasma binding of basic drugs. Trends Pharmacol. Sci., 2, 283–4
Garland, W.A., Muccino, R.R., Min, B.H., Cupano, J. and Fann, W.E. (1979). A method for the determination of amitriptyline and its metabolites nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline in human plasma using stable isotope dilution and gas chromatography-chemical ionization mass spectrometry (GC-CIMS). Clin. Pharmacol. Ther., 25, 844–56
Jeffrey, A.A. and Turner, P. (1978). Relationship between plasma and salivary concentrations of amitriptyline. Br. J. Clin. Pharmacol., 5, 268–9
Kragh-Sørensen, P. and Larsen, N.-E. (1980). Factors influencing nortriptyline steady-state kinetics: plasma and saliva levels. Clin. Pharmacol. Ther., 28, 796–803
Maitre, L., Moser, P., Baumann, P.A. and Waldmeier, P.C. (1980). Amine uptake inhibitors: criteria of selectivity. Acta Psychiat. Scand., 61, Suppl. 280, 97–110
Mellström, B., Bertilsson, L., Säwe, J., Schulz, H.-U. and Sjöqvist, F. (1981). E- and Z–10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin. Pharmacol. Ther., 30, 189–93
Mucklow, J.C., Bending, M.R., Kahn, G.C. and Dollery, C.T. (1978). Drug concentration in saliva. Clin. Pharmacol. Ther., 24, 563–70
Piafsky, K.M. and Borgå, O. (1977). Plasma protein binding of basic drugs. II. Importance of α1-acid glycoprotein for interindividual variation. Clin. Pharmacol. Ther., 22, 545–9
Posti, J. (1982). Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. Pharmaceut. Acta Helv., 57, 83–92
Potter, W.Z. (1981). Active metabolites of tricyclic antidepressants. In Clinical Pharmacology in Psychiatry; Neuroleptic and Antidepressant Research (ed. E. Usdin, S.G. Dahl, L.F. Gram and O. Lingjaerde), Macmillan, London, pp. 139–53
Routledge, P.A., Stargel, W.W., Finn, A.L., Barchowsky, A. and Shand, D.G. (1981). Lignocaine disposition in blood in epilepsy. Br. J. Clin. Pharmacol., 12, 663–6
Tinguely, D., Baumann, P. and Schöpf, J. (1982). A microprocedure to determine polymorphic forms of acid-α1-glycoprotein in plasma. Application to depressive patients treated with amitriptyline. J. Chromatogr., 229, 319–25
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1983 The contributors
About this chapter
Cite this chapter
Baumann, P. et al. (1983). The fate of amitriptyline and its metabolites, taking into account their binding in plasma. In: Gram, L.F., Usdin, E., Dahl, S.G., Kragh-Sørensen, P., Sjöqvist, F., Morselli, P.L. (eds) Clinical Pharmacology in Psychiatry. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-06671-1_21
Download citation
DOI: https://doi.org/10.1007/978-1-349-06671-1_21
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-06673-5
Online ISBN: 978-1-349-06671-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)